Skip to main content
. 2019 Jan 10;115(5):966–977. doi: 10.1093/cvr/cvz006

Figure 5.

Figure 5

Neuregulin-1β attenuates the ponatinib induced cardiac growth signalling perturbation in NRVMs. (A) NRVMs pretreated with 50 ng/mL Neuregulin-1β for 30 min followed by ponatinib treatments (50 nM–1µM) for 72 h. Cell viability assay was performed after 72 h. DMSO was used as vehicle control. Only ponatinib treated NRVMs were used for viability comparison. Data are presented as means ± SEM. Statistical analysis was conducted using two-way ANOVA post hoc Tukey test for comparison between ponatinib vs. ponatinib + Neuregulin-1β at each concentration (*P < 0.05, ***P < 0.001, ****P < 0.0001). (B–E) NRVMs were pretreated with 50 ng/mL for 30 min followed by 50 nM ponatinib treatment upto 12 h. After that, lysates were prepared using cell lysis buffer. Lysates were then subjected to western blot and probed with respective antibodies mentioned in the diagram. Tubulin serves as loading control. Bar diagram represents a densitometric analysis of western blots. Western blots are representative of three independent experiments. Data are presented as means ± SEM. Statistical analysis was conducted using two-way ANOVA post hoc Tukey test for comparison between groups (****P < 0.0001).